Scarica l'app Stockscreener
18.63
2.48%
0.45
Dopo l'orario di chiusura:
18.81
0.18
+0.97%
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event - marketscreener.com
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC (PR Newswire) - Aktiellt
JPMorgan Chase & Co. Has $7.06 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
(IDYA) Trading Report - news.stocktradersdaily.com
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha
IDEAYA advances darovasertib in uveal melanoma trial By Investing.com - Investing.com Nigeria
Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell - marketscreener.com
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Ph - GuruFocus
IDEAYA advances darovasertib in uveal melanoma trial - Investing.com Australia
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - BioSpace
Ideaya Biosciences Announces Successful FDA Type D Meeting for Darovasertib - MarketScreener
Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial - Stock Titan
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma (PR Newswire) - Aktiellt
Wellington Management Group LLP Has $1.02 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Geode Capital Management LLC Acquires 43,226 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Ideaya Biosciences (IDYA) Launches Expanded Phase 1/2 Trial for IDE397 in Cancer Treatment | GILD Stock News - GuruFocus
Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - marketscreener.com
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and - GuruFocus
Ideaya Biosciences Announces Phase 1/2 Expansion For Ide397 And Trodelvy® Combination In Mtap-Deletion Urothelial Cancer - marketscreener.com
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - Nasdaq
Indo-Asian News Service - Indo-Asian News Service (IANS)
Norges Bank Purchases Shares of 520,810 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - The AM Reporter
Vanguard Group Inc. Has $130.51 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Ideaya stock hits 52-week low at $14.09 amid market challenges By Investing.com - Investing.com South Africa
Ideaya stock hits 52-week low at $14.09 amid market challenges - Investing.com Australia
IDEAYA to Participate in Upcoming September 2020 Investor Relations Events - BioSpace
KLP Kapitalforvaltning AS Makes New $383,000 Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences announces board change and new advisory role By Investing.com - Investing.com South Africa
IDEAYA Biosciences announces board change and new advisory role - Investing.com
Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA) - Seeking Alpha
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events - BioSpace
IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences - Stock Titan
Where are the Opportunities in (IDYA) - news.stocktradersdaily.com
IDEAYA's Eye Cancer Therapy Receives Breakthrough Therapy Designation From FDA - MarketScreener
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation For Darovasertib Monotherapy In Neoadjuvant Uveal Melanoma - MarketScreener
Revolutionary Eye Cancer Drug Achieves FDA Breakthrough Status: 82% Tumor Shrinkage Rate - Stock Titan
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - The Malaysian Reserve
Ideaya Biosciences stock hits 52-week low at $16.95 By Investing.com - Investing.com South Africa
Ideaya Biosciences stock hits 52-week low at $16.95 - Investing.com
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
IDEAYA Awards $306K Worth of Stock Options to Strategic New Hire - Stock Titan
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - Marketscreener.com
(IDYA) Technical Pivots with Risk Controls - Stock Traders Daily
Ideaya Biosciences stock hits 52-week low at $17.28 By Investing.com - Investing.com Australia
Ideaya Biosciences stock hits 52-week low at $17.28 - Investing.com
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up – What’s Next? - Defense World
IDEAYA Announces Further Gilead Sciences Clinical Study Collabor - GuruFocus.com
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):